Sustained monomorphic VT in ischemic cardiomyopathy — amiodarone vs catheter ablation, which is first-line?

60M with ischemic cardiomyopathy (EF 30%), has ICD. Three ICD shocks in the past 6 months for sustained monomorphic VT at 180 bpm. Currently on amiodarone 200mg OD. Electrophysiology team suggests VT ablation. Is catheter ablation preferred over antiarrhythmic drug escalation at this point? What is the evidence from VANISH and SMASH-VT trials? What are the risks and success rates?